NEUROENDOCRINE CARCINOMA OF THE BREAST AND ILEUM IN A PATIENT WITH BRCA2 PATHOGENIC VARIANT – ONCOLOGIC AND GENETIC CONSIDERATIONS DERIVED FROM A CASE REPORT
DOI:
https://doi.org/10.29289/259453942022V32S2076Palavras-chave:
Breast cancer, BRCA2Resumo
Background: Neuroendocrine neoplasms (NENs) are a heterogeneous group of neoplasms. Most frequently, they occur
in the digestive system, and breast neuroendocrine tumors constitute less than 1% of all of them. Germline mutations
can increase the risk of developing tumors and predispose to hereditary cancer syndromes. Some NENs are well-established components of common hereditary syndromes. Recently, whole genomic sequencing revealed that 17% of apparently
sporadic pancreatic NENs carried germline mutations, including DNA repair genes, such as BRCAs. It is well known that
this gene plays a role in hereditary breast cancer, but variations in these genes were not described in patients with breast/
ileum neuroendocrine tumors. We present a patient with a neuroendocrine tumor and a germline pathogenic variant in
BRCA2. Case report: A 44-year-old female patient presented with a palpable lesion at the right breast, with 1.1×1.4 cm, and
a biopsy confirmed an invasive ductal carcinoma, grade 2. Immunohistochemistry revealed a neuroendocrine breast carcinoma (ER10% PR5%, HER2 negative, Ki-67=8%). The regular staging examinations did not show any abnormalities, but
a 68Ga PET/CT demonstrated an ileum wall thickening with a marked expression of somatostatin receptors compatible
with primary disease, with mesenteric lymph nodes and hepatic lesions suggestive of metastasis, in addition to the right
breast lesion that could be either a secondary implant or a primary synchronic tumor. A detailed family history did not
reveal any important cancer cases in the family except for the father and a paternal uncle, both with prostate cancer at
72 and 85 years old, respectively. Germline genetic analysis confirmed the presence of a heterozygous pathogenic variant
in BRCA2 (c.2167delA;p.Ser723Alafs*7). The patient is currently being treated with octreotide LAR with good tolerance
and stable disease. Final comments: This case shows the importance of molecular germline investigation in patients with
NENs. This patient adds knowledge to the association of the BRCA2 gene and neuroendocrine tumors.
Downloads
Downloads
Publicado
Como Citar
Edição
Seção
Licença
Copyright (c) 2026 Andreza Karine de Barros Almeida Souto, Poliana Bergamaschine Giovani Blasi, Brenda Fabiola Delgado Taboada, Fernanda Teresa Lima, Bernardo Garicochea, Cristiano Augusto Andrade de Resende

Este trabalho está licenciado sob uma licença Creative Commons Attribution 4.0 International License.




